Bisphosphonates in the treatment of osteoporosis

BMJ (Online)

Volumn 345, Issue 7869, 2012, Pages

  Poole, Kenneth E ^a   Compston, Juliet E ^b  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ETIDRONIC ACID; GENERIC DRUG; IBANDRONIC ACID; PARATHYROID HORMONE DERIVATIVE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ABDOMINAL PAIN; APOPTOSIS; ARTHRALGIA; BONE DENSITY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DYSPEPSIA; ESOPHAGITIS; FEMUR FRACTURE; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEADACHE; HIP FRACTURE; HUMAN; INHIBITION KINETICS; IRITIS; JAW OSTEONECROSIS; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NON VERTEBRA FRACTURE; NON VERTEBRAL FRACTURE; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMARKETING SURVEILLANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UVEITIS; VERTEBRA FRACTURE; AGED; ARTICLE; CASE REPORT; FEMALE; TREATMENT OUTCOME;

AGED; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; HIP FRACTURES; HUMANS; OSTEOPOROSIS; TREATMENT OUTCOME;

EID: 84864881852     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e3211     Document Type: Review

References (20)

1. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59.
2. Black D, Cummings S, Karpf D, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41. (Pubitemid 26411651)
3. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effect of risedronate treatment on vertebral and non vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 1999;282:1344-52. (Pubitemid 29483192)
4. Reginster JY, Minne H, Sorensen O, Hooper M, Roux C, Brandi ML, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91. (Pubitemid 30099515)
5. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8. (Pubitemid 39361949)
6. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22. (Pubitemid 46698462)
7. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001;344:333-40. (Pubitemid 32107641)
8. Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 2009;20:291-7.
9. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. New Engl J Med 2010;362:1761-71.
10. National Institute for Health and Clinical Excellence. Osteoporosis-secondary prevention including strontium ranelate. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. (Technical appraisal 161.) 2011. http://www.nice.org.uk/TA161.
11. National Institute for Health and Clinical Excellence. Osteoporosis-primary prevention. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. (Technical appraisal 160.) 2011. www.nice.org.uk/TA160.
12. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009;62:105-8.
13. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21. (Pubitemid 26338731)
14. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91. (Pubitemid 351229318)
15. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-94.
16. Compston J. Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw. Osteoporos Int 2011;22:2951-61.
17. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. New Engl J Med 2011;364:1728-37.
18. Kanis JA, Adams J, Borgstrom F, Cooper C, Jönsson B, Preedy D, et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone 2008;42:4-15.
19. Compston JE, Bilezikian JP. Bisphosphonate therapy for osteoporosis: the long and short of it. J Bone Miner Res 2012;27:240-2.
20. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis: for whom and how long? New Engl J Med 2012;9 May. epub ahead of print. doi:10.1056/NEJMp1202623.